Kun Y. Lee

TL;DR: To determine whether inherited germline mutations in cancer predisposition genes are associated with increased risks of pancreatic cancer, a case-control study of patients diagnosed as having pancreaticcancer and enrolled in a Mayo Clinic registry between October 12, 2000, and March 31, 2016 was conducted.

TL;DR: In this paper, population-based estimates of the risk of breast cancer associated with germline pathogenic variants in cancer-predisposition genes are critically needed for risk assessment and risk assessment.

TL;DR: A substantial proportion of women with breast cancer carrying germline pathogenic variants in predisposition genes do not qualify for testing by the National Comprehensive Cancer Network criteria, and expansion of NCCN criteria to include all women diagnosed at ≤ 65 years of age improves the sensitivity of the selection criteria without requiring testing of all women.

TL;DR: The study identifies genes that predispose to breast cancer in the AA population, demonstrates the validity of current breast cancer testing panels for use in AA women, and provides a basis for increased referral of AA patients for cancer genetic testing.

TL;DR: Findings provide insight into the spectrum of mutations expected in patients with pancreatic cancer referred for cancer predisposition testing and may prove useful for risk assessment for pancreatic and other cancers.